Stock FOLD AMICUS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Amicus Therapeutics, Inc.

Equities

FOLD

US03152W1099

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-10 pm EDT 		5-day change 1st Jan Change
9.23 USD -2.64% Intraday chart for Amicus Therapeutics, Inc. -11.25% -34.95%
May. 10 UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating MT
May. 09 Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
UBS Trims Price Target on Amicus Therapeutics to $19 From $20, Keeps Buy Rating
MT
Amicus Therapeutics' Q1 Net Loss Narrows, Net Product Sales Rise
MT
Transcript : Amicus Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024
Amicus Therapeutics: Q1 Earnings Snapshot
AQ
Amicus Therapeutics : 1Q24 Earnings Deck FINAL
PU
Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
AQ
Amicus Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
CI
Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
AQ
Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
AQ
Amicus Therapeutics : ESG Report
PU
Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
AQ
JPMorgan Adjusts Price Target on Amicus Therapeutics to $19 From $21, Maintains Overweight Rating
MT
Amicus Therapeutics Insider Sold Shares Worth $389,543, According to a Recent SEC Filing
MT
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
AQ
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
AQ
Transcript : Amicus Therapeutics, Inc., Q4 2023 Earnings Call, Feb 28, 2024
Amicus Therapeutics Swings to Q4 Earnings, Revenue Rises
MT
Earnings Flash (FOLD) AMICUS THERAPEUTICS Posts Q4 EPS $0.01, vs. Street Est of $-0.04
MT
Amicus Therapeutics, Inc. Provides Earnings Guidance for the Year 2024
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FOLD Stock
  4. News Amicus Therapeutics, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW